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RECENT ADVANCES IN BLOOD COAGULATION WITH 
REGARD TO ANTICOAGULANT THERAPY, FIBRINOGEN, 
HEMOPHILA AND PLATELET DISORDERS* 
SHIRLEY A. JOHNSON, Ph.D.** 
Studies in blood coagulation which have been pursued for many decades in 
clinical entities such as hemophilia have suddenly become important in laboratory 
medicine because of the use of the oral anticoagulants. The problem of intravenous 
clotting is not wefl understood and a great deal of attention is being given to it. Since 
it is not known what elements in blood render it hypercoagulable, one therapeutic 
approach is to render the blood less coagulable by the administration of oral anti-
coagulants. Prothrombin time is prolonged when any coumarin or phenindione drug 
is given. 
The prothrombin time (Table I ) is a general test involving the addition of tissue 
TABLE I 
PROTHROMBIN TIME 
PLASMA, OXALATED 0.1 ML. 
CACL2 0.1 ML. 
TISSUE THROMBOPLASTIN 0.1 ML. 
CLOT APPEARS I N 14 SECONDS 
thromboplastin and calcium to plasma and observing the time that the plasma takes 
to form a clot. I f excess or normal amounts of prothrombin and accelerators are 
present a short prothrombin time of approximately 14 seconds results. Our concepts 
of coagulation are shown simply in Table I I . The prothrombin time measures the 
components involved in the activation of prothrombin in the presence of tissue throm-
boplastin. The right side of the Table represents the activation of prothrombin without 
tissue thromboplastin but with platelets and the various co-factors of platelets which 
are normally found in plasma. Tissue thromboplastin is not normally present in the 
circulating blood and is thought to be released only from the surrounding tissue by a 
break in the surface of the blood vessel caused by trauma. The oral anticoagulants 
reduce prothrombin and autoprothrombin I , both of which affect the prothrombin time 
by prolonging fl, and autoprothrombin I I . Autoprothrombin I I is involved in one of 
the hemophilias and its concentration does not affect the prothrombin time. 
It is possible that the oral anticoagulants reduce or alter some other factor which 
has not yet been identified and that this unidentified component moves parallel to the 
two factors, prothrombin and autoprothrombin I , which do affect the prothrombin 
*Presented before the Blackwell Society, Womens Medical Society, Detroit May 14, 1958. 
** Department of Laboratories. 
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time. This unidentified component may be the more important factor in the prevention 
of thrombosis. I t is known that the prothrombin time gives an accurate gauge of the 
dosage of the oral anticoagulant, and fo r this reason fl is an important test in blood 
coagulation. 
Table I I shows that a smafl quantity of thrombin, just a fraction of a unit, w i l l 
greatly shorten the prothrombin time by converting the fibrinogen to f ib r in and 
eliminating the prothrombin to thrombin step. I f enough anticoagulant has been given 
T A B L E I I 
P R O T H R O M B I N 
TISSUE T H R O M B O P L A S T I N 
C A L C I U M 
A C - G L O B U L I N OR P l ^ A T i 
A U T O P R O T H R O M B I N 
A N T I H E M O P H I L I C F A C T O R 
U T O P R O T H R O M B I N I I 
L A T E L E T F A C T O R 3 
T H R O M B I N 
F I B R I N O G E N F I B R I N 
CONCEPT OF C O A G U L A T I O N 
to prolong a 14 second prothrombfli time to 30 seconds, a little thrombin can shorten 
this to 17. A physician may note a 17 second prothrombin time, expect 30 and increase 
the dose of anticoagulant. The next day instead of 30 seconds as expected he finds 
45. The small amount of thrombin should be kept out of the blood in the first place. 
The blood is mixed in the tube wi th sodium oxalate immediately after it is drawn. 
The tissue thromboplastin in the f o r m of tissue juices initiates the coagulation processes 
and that smafl amount of prothrombin is converted to thrombin and the cycle begins. 
Contrary to popular belief the prothrombin time of a specimen of plasma is constant 
throughout a day. Prothrombin and the accelerators involved in the activation of 
prothrombin are fair ly stable fo r eight hours or so at room temperature. What this 
means is that a prothrombin time is rarely falsely prolonged, but only falsely shortened. 
Except in the laboratory measurement of dosage of anticoagulant, the field of 
blood coagulation has contributed little to the management and understanding of 
thrombosis. The most important aspect of blood coagulation in the clinical sphere 
in the five next years w i l l be, no doubt, in the area of clot dissolving or fibrinolysim. 
While the method of preventing the formation of the clot is not yet avaflable, it does 
appear that more is known about how to dissolve the clot once it has formed. Wi th in 
the next five years an intravenous fibrinolysim wi l l probably be developed fo r thrombo-
phlebflis, intravascular thrombosis and even coronary thrombosis. The problem is that 
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normal blood contains a profibrinolysin in an inactive form and how fl is activated to 
active fibrinolysim has never been discovered. (Table I I I ) It may be an activator which 
is called urokinase because it is found in urine. Whether or not this is the actual in 
vivo method is not yet known for certain. Streptokinase is another activator of 
fibronolyism but is not the natural one. 
T A B L E I I I 
P R O F I B R I N O L Y S I N 
A C T I V A T O R S 
U R O K I N A S E 
S T R E P T O K I N A S E 
TISSUE A C T I V A T O R 
U N K N O W N SOURCE 
F I B R I N O L Y S I N 
F I B R I N D I S S O L V E D C L O T 
POSSIBLE A C T I V A T O R S OF P R O F I B R I N O L Y S I N 
In addition to finding the best and, if possible, the natural activator of profibrin-
olysin, another problem exists. Some investigators believe that once the clot has 
formed from the whole blood and sufficient profibrinolysin is incorporated into the 
clot, lysis wfll take place if activator alone is added so only one of the experimental 
intravenous preparations contains activator. Another intravenous preparation contains 
excess activator, as well as some profibinolysin, and, of course, the various activators 
vary. One of the most exciting races in the pharmaceutical industry is in this field. 
While intravenous clot prevention is probably a long way off, lysis of the intravenous 
clot is near at hand. 
The two aspects of blood coagulation so far discussed, namely, anticoagulant 
dosage control and administration of fibrinolysin are recent. Hemophilia, which has 
been known for centuries, is the time honored problem in blood coagulation. Prior 
to World War I I there was some debate about whether hemophiliacs bled due to a 
defect in their platelets or to a plasma defect. Brinkhous' showed that the hemophiflc 
platelets were normal when removed from normal blood but that the plasma recalcifi-
cation time was long. The prothrombin time is normal. This is easy to understand 
with reference to Table I I . The antihemophilic factor acts with platelets to activate 
prothrombin in a somewhat slower fashion than tissue thromboplastin but in a rather 
analagous way. Therefore formation of activity between platelets and the antihemo-
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phflic factor is called blood thromboplastin and can be measured by the thromboplastin 
generation test. The formation of blood thromboplastin requires neflher extravascular 
materials nor a break in the lining of the vessel. For these reasons, tissue thromboplastin 
added to the plasma will mask this formation of blood thromboplastin, and normal 
and hemophilic plasma will give a normal prothrombin time. (Table IV) 
TABLE IV 
LABORATORY TESTS I N HEMOPHILIA 
PROTHROMBIN TIME NORMAL 
PLASMA CLOTTING TIME 
(RECALCIFICATION TIME) 
PROLONGED 
CLOTTING TIME PROLONGED 
PROTHROMBIN CONSUMPTION TIME ABNORMALLY SHORT 
Classical hemophilia is concerned with a deficiency in the antihemophflic activity 
but the kind of defect is not agreed upon by investigators in this field. A controversy 
exists between those who believe that it represents the actual lack of a factor and those 
who believe that the antihemophilic factor is present but its activity is masked by 
association with an inhibitor. For practical purposes it does not matter as treatment 
would be the same regardless of the mechanism of the defect. The antihemophilic factor 
is unstable in whole blood or plasma. Perhaps it becomes conjugated with its inhibitor 
unstable in whole blood or plasma. Perhaps it becomes conjugated with its inhibitor 
as it does when blood clots for there is no antihemophflic activity in serum. Treatment 
of a hemophiliac is one of the rare instances in which fresh blood should be given. 
Many investigators recommend giving a bleeding hemophiliac blood which is less 
than 12 hours old. 
The above remarks pertain to classical hemophilia. In 1952 independently in 
California and in England another kind of hemophilia was described. The term hemo-
phflia has been enlarged to include any defect in the plasma factors which act with 
platelets. There are now considered to be at least two factors and some investigators 
believe there are more. Aggeler and associates' cafled their deficient factor plasma 
thromboplastin component and the disease PTC. Biggs and associates' named it 
Christmas disease from the name of their patient. (Table V) 
Whether the PTC factor or Christmas factor acts with the antihemophilic factor 
together with platelets or whether one acts with platelets to form a product which 
then acts with the other is not known. But the two components, the antihemophilic 
factor and PTC, do act with platelets in some rather complicated fashion. Hemophilia 
is a rare disaese. Most clinical bleeding problems are concerned with platelet distur-
bances. However, there are those who feel that platelets have no relation to coagulation. 
The thrombocytopenias, primary or secondary, comprise the largest group of 
bleeding problems. From an investigative point of view the coagulation of blood 
without platelets is a fascinating concept. It is considered that a platelet count of 
50,000 or less wifl cause bleeding and yet the whole blood clotting time or Lee White 
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TABLE V 
TYPES OF HEMOPHILIA 
NAME OF DISEASE FACTOR INVOLVED 
CLASSICAL HEMOPHILIA ANTIHEMOPHILIC FACTOR 
PTC DEFICIENCY OR PTC OR CHRISTMAS FACTOR 
CHRISTMAS DISEASE 
PTA DEFICIENCY PTA? 
of such blood is normal. Blood will clot in the thrombocytopenic state but it clots 
differently when an abundance of platelets is available. Blood clots differently when 
platelets are reduced as evidenced by the fact that the prothrombin consumption time 
is greatly shortened in thrombocytopenic serum. 
The prothrombin consumption time is based on the Quick prothrombin time, the 
difference being that the prothrombin consumption time is carried out on serum. In 
normal serum the prothrombin is reduced from about 250 units per millflitre to about 
20 units and some accelerators of prothrombin activation are formed as blood clots. 
If prothrombin time is carried out on normal serum, that is the addition of thrombo-
plastin and fibrinogen, instead of a value of 14 seconds one of 30 or more is found. 
So the normal prothrombin consumption time is prolonged and if the coagulation is 
incomplete and residual prothrombin remains in the serum the prothrombin consumption 
time is shortened. The prothrombin time is easily carried out if the serum is carefully 
defined such as whole blood that has been permitted to clot for one hour at a 
standard temperature. The end products of coagulation differ considerably depending 
on the time that serum is examined. The thrombin, which forms when blood clots, 
disappears due to the action of antithrombin. As a result, serum 30 minutes old contains 
thrombin which is almost completely absent in serum 60 minutes old. 
If platelets are reduced to the thrombocytopenic state the prothrombin consump-
tion time on such blood is shortened abnormally. However, there is little or no 
residual prothrombin in the serum. The short prothrombin consumption is due to 
the formation in abnormal amounts of an accelerator when blood clots. It is probable 
that this accelerator is a derivative of prothrombin because chemically it resembles 
prothrombin. From an investigative point of view the mechanism of action of blood 
coagulation in the thrombocytopenic state is an intensely interesting one. However, 
at the moment the therapeutic problem must be approached from the other end, that 
is, replacement of platelets. 
Platelet transfusions and platelet substitutes are used in various parts of the 
country. Whole fresh human platelets are the logical source but economically this 
presents problems. However, most platelets in bank blood are lost because the platelets 
have disintegrated before the blood is transfused. It is feasible to collect the platelets 
from each pint of blood as the blood comes into the blood bank and to lyophilize the 
platelets and store them till needed. The most active factor in platelets, platelet factor 
3 or the thromboplastic factor of platelets, is destroyed with lyophilization which is a 
disadvantage of this method. Huge quantities of platelets are required to control 
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bleeding. An attempt to use a purified platelet factor 3 preparation from bovine 
sources in secondary thrombocytopenia has been made at the Henry Ford Hospflal 
with some success." There have been no antigenic problems, perhaps because the 
reticulo-endothelial system is damaged in these patients. This bovine platelet preparation 
is sterflized using beta-propriolactone and ultraviolet radiation.' However, as yet the 
best platelet substitute has not been worked out. 
Another aspect of platelet work is concerned with a group of fifteen patients 
who bleed because of defective platelets.' The condition is designated as thrombocyto-
pathy. This group of fifteen patients had mfld bleeding manifestation, and most 
laboratory findings were normal except the bleeding time which was over 20 minutes 
and the prothrombin consumption time which was 14 seconds. This suggested a 
platelet dysfunction and the platelets were collected from 100 ml. of blood and 
assayed in the thromboplastin generation test. It was found that a suspension of equal 
numbers of normal platelets generated more thromboplastic activity than those of 
the patients. There are many platelet factors but we feel that the one most responsible 
for activation of prothrombin and generation of blood thromboplastin is probably 
platelet factor 3. This platelet activity is also specific for platelets. There is no 
comparable activity in plasma. Using a specific platelet factor 3 assay involving 
the activation of purified prothrombin in the presence of the antihemophilic activity 
the platelets from these patients activated less than one hundred unfls of prothrombin 
to thrombin while platelets activated 800 units per mfllitre. 
Rebuck and associates' studied these platelets morphologically using the phase 
and electron microscopes. It is considered that platelets pass through four stages in 
the process of disintegration. The round or circulating type which is opaque to electrons 
is believed to become the dendritic form. The dedritic form changes into the inter-
mediate form and then to the less dense spread type. Electron micrographs of normal 
blood show most of the platelets in the dendritic stage. The platelets of these patients, 
however, are mostly in the spread stage. A platelet count of the blood of seven of the 
patients was carried out under the electron miscroscope and revealed about 26 per 
cent of their platelets to be in the dendritic stage, compared to 80 per cent of the 
platelets in normal blood. It is possible that this represented a kind of platelet that 
did not rupture easily and so could account for the pile-up at this later stage. This 
would mean that the platelets of these patients had adequate amounts of platelet factor 
3 but could not release it. This was tested by disintegrating the platelets in a sonic 
oscfllator and measuring the platelet factor 3 activity. The activity of these patients' 
platelets has increased from the ability to activate 200 units per millflitre of purified 
prothrombin to thrombin to 600 units per millilitre, when they are thoroughly disinte-
grated. We feel that we have elucidated, in part, the fault in these platelets but what 
the satisfactory therapeutic measure will be is another problem. 
Another aspect of platelet dysfunction has been found in uremia. Some uremics 
bleed. The laboratory tests in coagulation appear to be normal except that the 
prothrombin consumption test in some cases is abnormally short. Like the throm-
bocytopenic state and thrombocytopathy this short prothrombin consumption was 
not due to residual prothrombin but probably due to the formation of an accelerator. 
Platelets from the uremic patients are obtained by differential centrifuga.tion from 
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too ml. whole blood, washed in saline three times, and then resuspended in saline at a 
known concentration per cu.mm. These fresh whole platelets were used to determine 
clot retraction by the method suggested by Hartman and Conley.' The uremic plasma 
and platelets were compared with that of normal and found to have normal retraction. 
Platelet factor 3 assays were carried out and found to be markedly decreased. 
Previous studies on thrombocytopathy A showed that platelets deficient in factor 3 
would give normal activity after being fragmented by sonic treatment. This procedure 
was carried out on the uremic platelets, but no increase in activity was obtained. This 
suggests that the defect in uremia is different from that in thrombocytopathy A. It 
has been postulated that in thrombocytopathy A the platelet factor 3 activity is present 
in normal amounts; however, the platelets do not disintegrate normally to release 
it. But in the uremic condition the platelets appear to be actually deficient in the 
activity. Preliminary studies done by electron microscopy have shown the uremic 
platelets to be normal morphologically.' A considerable study on morphology of 
thrombocytopathy A platelets have shown them to be abnormal morphologically. 
Possibly this difference in morphology is closely related to the difference in the activity 
obtained in thrombocytopathy A after sonic treatment and the lack of activity obtained 
from uremic patients' platelets. 
Thromboplastin generation tests were done using platelets harvested from uremic 
platelets and these were found to generate far less thromboplastin than platelets from 
normal individuals. Since many metabolites in the blood are altered in uremia, the 
possibflity arises that they could be responsible for the destruction of platelet activity. 
To test this possibility, normal platelets were suspended in uremic plasma and 
incubated at 8° C for 18 hours. Then the platelets were centrifuged and washed 
and their activity tested. The platelet factor 3 activity of this platelet extract was 
greatly decreased. The thromboplastin generation test was also done and it was found 
the platelets which had been incubated in uremic plasma did not generate as much 
thromboplastin as those incubated in normal plasma. It is too early in this investigation 
to be able to draw any definite conclusions, but the cause of the loss of platelet factor 
3 activity wifl probably be closely associated with the metabolites of uremia. 
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